Silencing LRH-1 in Colon Cancer Cell Lines Impairs Proliferation and Alters Gene Expression Programs
Overview
Affiliations
Colorectal cancers (CRCs) account for nearly 10% of all cancer deaths in industrialized countries. Recent evidence points to a central role for the nuclear receptor liver receptor homolog-1 (LRH-1) in intestinal tumorigenesis. Interaction of LRH-1 with the Wnt/β-catenin pathway, highly active in a critical subpopulation of CRC cells, underscores the importance of elucidating LRH-1's role in this disease. Reduction of LRH-1 diminishes tumor burden in murine models of CRC; however, it is not known whether LRH-1 is required for tumorigenesis, for proliferation, or for both. In this work, we address this question through shRNA-mediated silencing of LRH-1 in established CRC cell lines. LRH-1 mRNA knockdown results in significantly impaired proliferation in a cell line highly expressing the receptor and more modest impairment in a cell line with moderate LRH-1 expression. Cell-cycle analysis shows prolongation of G0/G1 with LRH-1 silencing, consistent with LRH-1 cell-cycle influences in other tissues. Cluster analysis of microarray gene expression demonstrates significant genome wide alterations with major effects in cell-cycle regulation, signal transduction, bile acid and cholesterol metabolism, and control of apoptosis. This study demonstrates a critical proproliferative role for LRH-1 in established colon cancer cell lines. LRH-1 exerts its effects via multiple signaling networks. Our results suggest that selected CRC patients could benefit from LRH-1 inhibitors.
Wang Y, Bendre S, Krauklis S, Steelman A, Nelson E Endocrinology. 2025; 166(4).
PMID: 39951497 PMC: 11878532. DOI: 10.1210/endocr/bqaf031.
Zhao R, Guo Z, Lu K, Chen Q, Riaz F, Zhou Y Cell Death Dis. 2024; 15(10):770.
PMID: 39438459 PMC: 11496806. DOI: 10.1038/s41419-024-07151-1.
Delineating the role of nuclear receptors in colorectal cancer, a focused review.
Manickasamy M, Jayaprakash S, Girisa S, Kumar A, Lam H, Okina E Discov Oncol. 2024; 15(1):41.
PMID: 38372868 PMC: 10876515. DOI: 10.1007/s12672-023-00808-x.
Ye W, Ya-Xuan C, Shan-Shan T, Qiu L, Ting M, Shao-Jie C Immun Inflamm Dis. 2024; 12(2):e1172.
PMID: 38358044 PMC: 10868143. DOI: 10.1002/iid3.1172.
Ahmed A, Reinhold C, Breunig E, Phan T, Dietrich L, Kostadinova F Mol Oncol. 2023; 17(8):1545-1566.
PMID: 36861295 PMC: 10399709. DOI: 10.1002/1878-0261.13414.